Shandong Xinhua Pharmaceutical Co (SZSE:000756) 3-Year EBITDA Growth Rate : 4.90% (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co 3-Year EBITDA Growth Rate?

Shandong Xinhua Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.26.

During the past 12 months, Shandong Xinhua Pharmaceutical Co's average EBITDA Per Share Growth Rate was -2.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 4.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shandong Xinhua Pharmaceutical Co was 66.70% per year. The lowest was -33.90% per year. And the median was 10.05% per year.

Competitive Comparison of Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Shandong Xinhua Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Shandong Xinhua Pharmaceutical Co (SZSE:000756) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Shandong Xinhua Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Xinhua Pharmaceutical Co (SZSE:000756) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (SZSE:000756) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

00719:Hong Kong XIN:Germany

Address

No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086

Website

http://www.xhzy.com

Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (SZSE:000756) Headlines

No Headlines